841301-32-4 Usage
Description
ASP 2151 is a helicase-primase inhibitor with potent antiviral activity against herpes simplex viruses (HSVs), particularly HSV-1 and HSV-2, as well as varicella-zoster virus (VZV). It effectively inhibits the replication of these viruses in human embryonic fibroblast (HEF) cells and demonstrates low cytotoxicity.
Uses
Used in Antiviral Therapy:
ASP 2151 is used as an antiviral agent for the treatment of infections caused by herpes simplex viruses (HSV-1 and HSV-2) and varicella-zoster virus (VZV). It exhibits inhibitory effects on the replication of these viruses in human embryonic fibroblast (HEF) cells, with EC50 values of 0.047, 0.036, and 0.028 μM for VZV, HSV-1, and HSV-2, respectively. Additionally, it has shown to increase the survival of cutaneously HSV-1-infected mice in a zosteriform-spread model of progressive HSV-1 infection, with an ED50 of 1.9 mg/kg twice per day.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ASP 2151 is used as a key component in the development of antiviral drugs targeting herpes simplex viruses and varicella-zoster virus. Its potent antiviral activity and low cytotoxicity make it a promising candidate for the treatment of viral infections caused by these viruses.
Check Digit Verification of cas no
The CAS Registry Mumber 841301-32-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,1,3,0 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 841301-32:
(8*8)+(7*4)+(6*1)+(5*3)+(4*0)+(3*1)+(2*3)+(1*2)=124
124 % 10 = 4
So 841301-32-4 is a valid CAS Registry Number.
841301-32-4Relevant articles and documents
NEW PROCESS FOR THE PREPARATION OF AMENAMEVIR
-
, (2020/12/30)
The present invention relates to an improved process for the preparation of Amenamevir and derivatives thereof via a four component Ugi reaction.
AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION
-
, (2009/10/31)
The present invention relates to a pharmaceutical composition containing a solid dispersion comprising an amide derivative or a salt thereof and a water-soluble polymer, wherein the pharmaceutical composition is not prepared by a melting method. The pharmaceutical composition contains the solid dispersion having an improved oral absorption, properties suitable for formulation, and an excellent stability.
AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS
-
Page/Page column 8; 13, (2008/06/13)
[PROBLEMS] To provide an agent useful for the prevention or treatment of various diseases associated with the infection with acyclovir-resistant viruses of the family Herpesviridae, specifically various infectious caused by herpesviruses, such as varicell
